AIMS: Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, we investigated whether serum irisin levels are decreased in patients with type 2 diabetes (T2D) compared with control subjects with normal glucose tolerance (NGT), and assessed the association between serum irisin levels and various metabolic parameters. METHODS: The study population was selected from a population-based study and included 104 subjects with NGT and 104 subjects with new-onset T2D. Serum irisin and adiponectin levels and metabolic parameters were measured. Multivariate logistic regression analysis was performed to assess the association between irisin levels and newly diagnosed T2D. RESULTS: Serum irisin levels were significantly decreased in the new-onset T2D group compared with the NGT control group (p=0.003). In a multivariable model adjusted for various metabolic parameters, increased irisin levels were associated with reduced odds (OR 0.64, 95% CI 0.47-0.88, p=0.006) of prevalent newly diagnosed T2D. Furthermore, multiple regression analysis showed that 2 h plasma glucose was an independent variable influencing serum irisin levels (p=0.004). CONCLUSION: In the present study, we found that serum irisin levels were decreased in T2D patients and inversely associated with newly diagnosed T2D, suggesting that irisin may play a crucial role in glucose intolerance and T2D.
AIMS: Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, we investigated whether serum irisin levels are decreased in patients with type 2 diabetes (T2D) compared with control subjects with normal glucose tolerance (NGT), and assessed the association between serum irisin levels and various metabolic parameters. METHODS: The study population was selected from a population-based study and included 104 subjects with NGT and 104 subjects with new-onset T2D. Serum irisin and adiponectin levels and metabolic parameters were measured. Multivariate logistic regression analysis was performed to assess the association between irisin levels and newly diagnosed T2D. RESULTS: Serum irisin levels were significantly decreased in the new-onset T2D group compared with the NGT control group (p=0.003). In a multivariable model adjusted for various metabolic parameters, increased irisin levels were associated with reduced odds (OR 0.64, 95% CI 0.47-0.88, p=0.006) of prevalent newly diagnosed T2D. Furthermore, multiple regression analysis showed that 2 h plasma glucose was an independent variable influencing serum irisin levels (p=0.004). CONCLUSION: In the present study, we found that serum irisin levels were decreased in T2D patients and inversely associated with newly diagnosed T2D, suggesting that irisin may play a crucial role in glucose intolerance and T2D.
Authors: W Farrash; M Brook; H Crossland; B E Phillips; J Cegielski; D J Wilkinson; D Constantin-Teodosiu; P L Greenhaff; K Smith; M Cleasby; P J Atherton Journal: Am J Physiol Endocrinol Metab Date: 2020-05-05 Impact factor: 4.310
Authors: Fabian Sanchis-Gomar; Rafael Alis; Helios Pareja-Galeano; Eva Sola; Victor M Victor; Milagros Rocha; Antonio Hernández-Mijares; Marco Romagnoli Journal: Endocrine Date: 2014-02-08 Impact factor: 3.633
Authors: A E Huerta; P L Prieto-Hontoria; M Fernández-Galilea; N Sáinz; M Cuervo; J A Martínez; M J Moreno-Aliaga Journal: J Physiol Biochem Date: 2015-03-28 Impact factor: 4.158
Authors: Mathias Schlögl; Paolo Piaggi; Susanne B Votruba; Mary Walter; Jonathan Krakoff; Marie S Thearle Journal: Appetite Date: 2015-03-09 Impact factor: 3.868
Authors: Timea Kurdiova; Miroslav Balaz; Marek Vician; Denisa Maderova; Miroslav Vlcek; Ladislav Valkovic; Miroslav Srbecky; Richard Imrich; Olga Kyselovicova; Vitazoslav Belan; Ivan Jelok; Christian Wolfrum; Iwar Klimes; Martin Krssak; Erika Zemkova; Daniela Gasperikova; Jozef Ukropec; Barbara Ukropcova Journal: J Physiol Date: 2013-12-02 Impact factor: 5.182